Current role of oral etoposide in the management of small cell lung cancer

Drugs

Volumn 58, Issue SUPPL. 3, 1999, Pages 17-20

  Clark, Peter I ^a  

^a CLATTERBRIDGE CENTRE FOR ONCOLOGY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; NAVELBINE; PACLITAXEL; TAXANE DERIVATIVE; TOPOTECAN; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; DRUG BIOAVAILABILITY; HUMAN; LUNG SMALL CELL CANCER;

EID: 0033510485     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199958003-00003     Document Type: Conference Paper

References (18)

1. Clark PI, Slevin ML. The clinical pharmacology of etoposide and teniposide. Clin Pharmacokinet 1987; 12: 223-52
2. Slevin ML, Clark PI, Joel SP, et al. A randomised trial to evaluate the effect of schedule on the activity of eloposide in SCLC. J Clin Oncol 1989; 7: 1333-40
3. Abratt RP, Willcox PA, de Groot M, et al. Prospective study of etoposide scheduling in combination chemotherapy for limited disease SCLC. Eur J Cancer 1991; 27: 28-30
4. Clark PI, Slevin ML, Joel SP, et al. A randomised trial of two etoposide schedules in small cell lung cancer: the influence of pharmacokinetics on efficacy and toxicity. J Clin Oncol 1994; 12: 1427-35
5. Clark PI, Slevin ML, Joel SP. A pharmacokinetic hypothesis for the clinical efficacy of etoposide in SCLC. Proc Am Soc Clin Oncol 1989; 8: 66A
6. Hainsworth JD, Johnson DH, Frazier SR, et al. Chronic daily administration of oral etoposide - a phase I trial. J Clin Oncol 1989; 7: 396-401
7. Johnson DH, Hainsworth JD, Hande KR, et al. Combination chemotherapy with oral etoposide. Semin Oncol 1992; 19 Suppl. 14: 19-24
8. Clark PI, Cottier B. The activity of 10-, 14-, and 21-day schedules of single-agent etoposide in previously untreated patients with extensive SCLC. Semin Oncol 1992; 19 Suppl. 14: 36-9
9. Carney DN, Keane M, Grogan L. Oral etoposide in SCLC. Semin Oncol 1992; 19 Suppl. 14: 40-4
10. Miller AA, Herndon JE, Hollis DR, et al. Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive stage small cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B. J Clin Oncol 1995; 13: 1871-9
11. Girling DJ. Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicentre randomised trial. Medical Research Council Lung Cancer Working Party. Lancet 1996; 348: 563-6
12. Clark PI, Thatcher N, Lallemand G, et al. Updated results of a randomised trial confirm that oral etoposide alone is inadequate palliative chemotherapy for small cell lung cancer. Lung Cancer 1997; 18: 14A
13. Souhami RL, Spiro SG, Rudd RM, et al. Five-day oral etoposide treatment for advanced small-cell lung cancer: randomised comparison with intravenous chemotherapy. J Natl Cancer Inst 1997; 89: 577-80
14. Johnson DH, Ruckdeschel JC, Keller JH, et al. A randomized trial to compare intravenous and oral etoposide in combination with cisplatin for the treatment of small cell lung cancer. Cancer 1991; 67 Suppl. 1: 245-9
15. Evans WK, Radwi A, Tomiak E, et al. Oral etoposide and carboplatin. Effective therapy for elderly patients with small cell lung cancer. Am J Clin Oncol 1995; 18: 149-55
16. Pfeiffer P, Sorensen P, Rose C. Is carhoplatin and oral etoposide an effective and feasible regimen in patients with SCLC? Eur J Cancer 1995; 31A: 64-9
17. Wolff AC, Ettinger DS, Neuberg D, et al. Phase II study of ifosfamide, carboplatin and oral etoposide chemotherapy for extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group pilot study. J Clin Oncol 1995; 13: 1615-22
18. Hainsworth JD, Gray JR, Stroup SL, et al. Paclitaxel, carhoplatin and extended-schedule eloposide in the treatment of SCLC: comparison of sequential phase II trials using different dose-intensities. J Clin Oncol 1997; 15: 3464-70